Melillo DG - Search Results

1

A receptor in pituitary and hypothalamus that functions in growth hormone release.

Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LH. Howard AD, et al. Among authors: melillo dg. Science. 1996 Aug 16;273(5277):974-7. doi: 10.1126/science.273.5277.974. Science. 1996. PMID: 8688086

2

Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor.

Dean DC, Nargund RP, Pong SS, Chaung LY, Griffin P, Melillo DG, Ellsworth RL, Van der Ploeg LH, Patchett AA, Smith RG. Dean DC, et al. Among authors: melillo dg. J Med Chem. 1996 Apr 26;39(9):1767-70. doi: 10.1021/jm960054c. J Med Chem. 1996. PMID: 8627599 No abstract available.

3

The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.

Halpin RA, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN, Melillo D, Doss G, Vyas KP. Halpin RA, et al. Drug Metab Dispos. 2000 Oct;28(10):1244-54. Drug Metab Dispos. 2000. PMID: 10997947

4

Synthesis of the first sulfur-35-labeled hERG radioligand.

Raab CE, Butcher JW, Connolly TM, Karczewski J, Yu NX, Staskiewicz SJ, Liverton N, Dean DC, Melillo DG. Raab CE, et al. Among authors: melillo dg. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1692-5. doi: 10.1016/j.bmcl.2005.12.021. Epub 2006 Jan 11. Bioorg Med Chem Lett. 2006. PMID: 16377185

5

Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques.

Baillie TA, Halpin RA, Matuszewski BK, Geer LA, Chavez-Eng CM, Dean D, Braun M, Doss G, Jones A, Marks T, Melillo D, Vyas KP. Baillie TA, et al. Drug Metab Dispos. 2001 Dec;29(12):1614-28. Drug Metab Dispos. 2001. PMID: 11717181

6

TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates.

Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, Pike A, Sur C, Melillo D, Bristow L, Bromidge F, Ragan I, Kerby J, Street L, Carling R, Castro JL, Whiting P, Dawson GR, McKernan RM. Atack JR, et al. J Pharmacol Exp Ther. 2006 Jan;316(1):410-22. doi: 10.1124/jpet.105.089920. Epub 2005 Sep 23. J Pharmacol Exp Ther. 2006. PMID: 16183706

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6 results

Search Page